Forbion European Acquisition filed to offer 10 million units, each priced at $10 and consisting of one Class A ordinary share and one-third of a warrant. The sponsor has committed to the purchase of up to $7.68 million in the SPAC’s warrants.
Forbion will focus on life sciences companies in Europe.
CEO and Director Jasper Bos, Ph.D. is a former Merck executive. Before joining Forbion he was senior vice president and managing director at M Ventures, leading the venture capital arm of Merck.
UBS and Kempen are joint book-running managers of the offering.
The SPAC has applied to list on the Nasdaq under FRBNU. Read more.
